A Study of LY3437943 in Participants With Type 2 Diabetes
J1I-MC-GZBD - ClinicalTrials.gov - NCT04867785
The main purpose of this study is to evaluate the efficacy and safety of LY3437943 in participants with type 2 diabetes (T2D) who failed to achieve adequate glycemic control on diet and exercise alone or on a stable dose of metformin.
Trial Summary
Age Range
18 - 75 yearsConditions the trial is for
Type 2 DiabetesWhat the trial is testing?
LY3437943, DulaglutideCould I receive a Placebo?
YesEnrollment Goal
281Trial Dates
May 13, 2021 - Oct 27, 2022How long will I be in the trial?
Your participation could last about 43 weeks and may include up to 14 visits to the study center.Trial Phase
IIKey Requirements
Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.Participants Must:
Participants must have type 2 diabetes
Participants must have received metformin along with diet and exercise in the last 3 months
Participants must have stable body weight for the last three months
Participants Must Not:
Participants must not have type 1 diabetes
Participants must not have ketoacidosis
Participants must not have retinopathy, maculopathy
- Participants must not have pancreatitisParticipants must not have high blood pressure
Lilly Trial Alerts
Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.
Clinical Trial Resources
You will complete the questionnaire on another website.YesNo